A predictive model for anlotinib-osimertinib efficacy in advanced non-small cell lung cancer with acquired resistance: circulating tumor DNA and angiogenesis markers
Meng Liu · American Journal of Translational Research · 2025
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
American Journal of Translational Research · e-Century Publishing Corporation · article · 2025
Abstract
OBJECTIVE: To develop a predictive model for the efficacy of anlotinib combined with osimertinib in treating advanced non-small cell lung cancer (NSCLC) with acquired resistance, based on circulating tumor DNA (ctDNA) clearance and angiogenesis markers. METHODS: We retrospectively analyzed data from 378 patients with acquired resistance advanced NSCLC treated at Shanghai University Mengchao Cancer Hospital between November 2020 and October 2022. Patients were divided into a monotherapy group (n=181, receiving osimertinib alone) and a combination therapy group (n=197, receiving anlotinib plus osimertinib).
The combination therapy group was further stratified into two subgroups based on progression-free survival (PFS): better efficacy (PFS ≥16 months) and poorer efficacy (PFS <16 months). Venous blood samples were collected before and after two treatment cycles for ctDNA detection using next-generation sequencing (NGS) and measurement of angiogenesis markers using electrochemiluminescence immunoassays. Multivariate logistic regression was employed to identify independent predictors, and a nomogram predictive model was constructed and validated. RESULTS: The combination therapy group demonstrated significantly longer PFS and overall survival compared to the monotherapy group.
After two treatment cycles, the combination therapy group showed a significant reduction in ctDNA levels, variant allele frequency (VAF), and a higher clearance rate of the T790M mutation. Additionally, angiogenesis markers were significantly lower in the combination therapy group post-treatment (all P<0.05). Multivariate logistic regression identified significant predictors of poor therapeutic effect. The nomogram model exhibited excellent predictive performance, with an AUC of 0.912 in the training set and 0.959 in the test set.
CONCLUSION: The developed nomogram reliably predicts the efficacy of anlotinib combined with osimertinib in treating acquired resistance NSCLC, offering valuable guidance for personalized treatment decisions.
Open the resolved locator · 10.62347/htag4562
Metadata licence: OpenAlex metadata (CC0)